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Comorbidity among patients with colon cancer in 
New Zealand 
Diana Sarfati, Lavinia Tan, Tony Blakely, Neil Pearce 
Abstract 
Aims To identify patient factors that are associated with a higher risk of comorbidity, 
and to assess the impact of comorbidity on risk of in-hospital death, length of stay and 
5-year all-cause survival among a large cohort of patients with colon cancer in New 
Zealand. 
Methods Comorbidity data were collected from patients who were diagnosed with 
colon cancer and admitted to public hospitals during 1996–2003. The comorbidity 
measures included all conditions listed in the Charlson Comorbidity Index, as well as 
a predetermined list of additional conditions. We examined predictors of higher 
comorbidity scores. We also measured the impact of comorbidity on in-hospital death, 
length of stay and 5-year all-cause survival using logistic, linear and Cox proportional 
hazard regression models to adjust for confounding by sex, age, ethnicity, extent of 
disease and area level deprivation. 
Results There were 11,524 patients included in the study. 7.5% of females and 10.3% 
of men had Charlson scores of three or more. Higher comorbidity scores were 
associated with increasing age, and were more common among males, Māori and 
Pacific people, those with unknown extent of disease and those living in the most 
deprived quintile of New Zealand. Those with Charlson scores ≥3 had a higher risk of 
in-hospital death (OR=4.8; 95% CI 3.5–6.6), longer lengths of hospital stay (0.14 
days 95% CI 0.08–0.2) and lower 5-year survival HR=2.0; 95%CI=1.8–2.3) 
compared with those with a score of 0.  
Conclusion This study confirms that comorbidity is common among colon cancer 
patients in New Zealand, and has an adverse and independent effect on outcomes 
related to mortality and length of hospital stay. 
Comorbidity is the coexistence of diseases or conditions with a disease of interest.1 
Studies in other countries have found that regardless of the primary disease in 
question, comorbidity is associated with poorer quality of life, longer and more 
expensive hospital stays, and poorer survival.2–4 There has been little work published 
on the prevalence or impact of comorbidity among patients in New Zealand.  
A paper by Davis et al5 involved a hospital notes review of 1575 patients from the 
Auckland region in which screeners identified comorbid disease using the Charlson 
comorbidity index. Māori ethnicity, and living in more deprived areas were associated 
with comorbidity, which in turn was associated with a range of adverse outcomes 
including length of stay and inpatient mortality. However, the authors were not able to 
adjust the analyses for primary diagnosis other than through major diagnostic 
category of primary condition (e.g. circulatory system, digestive system). This is 
important because primary diagnosis is likely to have strongly confounded the 
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relationships between risk factors, comorbidity and adverse outcomes. Other studies 
have investigated the role of comorbidity in mediating cancer related outcomes.6–8  
The study reported here uses routine data to focus on both the factors that predict 
comorbidity, and the impact of comorbidity measured using in-hospital death, length 
of stay and 5-year all-cause survival, among patients in the New Zealand context.  
This study was carried out among a large group of patients admitted to hospital for 
surgical resection of colon cancer. We selected colon cancer for several reasons. First, 
for a subset of those with colon cancer, we had specific study data available to 
validate the comorbidity information held in routinely collected administrative 
datasets.9  
Second, there is evidence that comorbidity affects outcomes from colon cancer both 
through the additional physiological burden of disease among those with comorbidity, 
and indirectly through the impact of comorbidity on treatment decisions.6 Third, colon 
cancer affects mainly older people among whom comorbidity is relatively common.10 
Finally, colon cancer is not strongly associated with risk factors that are 
simultaneously risk factors for other major causes of comorbidity and death (such as 
cardiovascular disease). 
This paper therefore aims to address three key questions. Firstly, how common is 
comorbidity in a large cohort of colon cancer patients in New Zealand? Secondly, 
what factors predict higher levels of comorbidity in this cohort? And finally, to what 
extent does comorbidity predict in-hospital death, length of stay and 5-year survival 
for patients admitted for surgical resection of colon cancer? 
Methods 
Patients were identified from the New Zealand Cancer Registry with a primary tumour in the colon 
(ICD-10-AM site codes C18-C19 excluding 18.1) and morphology consistent with adenocarcinoma, 
diagnosed between 1996 and 2003. Patients were ineligible if they were less than 25 years of age at 
diagnosis, were normally resident outside New Zealand, had a previous diagnosis of colon cancer, or 
were diagnosed after death.  
Routine hospital discharge data coded to ICD-9-CM-A were obtained from New Zealand Health 
Information Service in 2005. We treated the first admission for surgical resection of colon cancer as the 
index admission. Where a patient did not receive surgical resection, we treated the first hospital 
admission with colon cancer as primary diagnosis as the index admission. Those without such an 
admission were excluded from the study. We used both principal and secondary diagnosis fields to 
identify comorbid conditions using an 8-year lookback period, this being the longest possible time for 
lookback for the earliest cancer registrations. 
We identified all conditions included in the Charlson comorbidity index, as well as some additional 
conditions, listed in Table 1. The Charlson index was developed in 1987 using data from a cohort of 
607 medical patients, and validated with a population of breast cancer patients.11 Nineteen conditions 
are allocated a weight of 1 to 6 depending on the adjusted relative risk of 1-year mortality, and summed 
to give an overall score. A score of 0 indicates that none of these conditions were present, and higher 
scores indicate higher levels of comorbidity. 
We used the Charlson index scores either uncategorised (when used as a dependent variable in 
regression) or categorised into 0, 1, 2 or 3+ (when used as a predictor of the outcome variables), and 
we also investigated the roles of specific comorbid conditions. 
We used the Deyo et al12 system which provides a method of translating the Charlson index which was 
originally constructed using medical notes review for use on administrative data using ICD coding. The 
algorithm was modified to take account of the fact that we collected data on additional conditions to 
those included in the Charlson Index (Table 1).  
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We followed the approach of Deyo et al,12 except that we included non-colorectal malignancies in our 
definition of comorbidity if they were listed in index or prior hospital discharges.13 
 
Table 1. Diagnostic codes used for mapping 
 
Diagnostic category ICD-9 codes 
Myocardial infarction 410.x, 412* 
Congestive heart failure 428.x 
Peripheral vascular disease 441.x*, 443.9*, 785.4*, V43.4*, procedure 38.48 
Cerebrovascular disease 430-437.x, 438* 
Dementia 290.x* 
Chronic respiratory disease 490-496*, 500-505*, 506.4* 
Connective tissue disease 710.0-710.1*, 710.4*, 714.0-714.2*, 714.81*, 725* 
GI ulcer disease 531.x-534.9* 
Mild liver disease 571.2*, 571.4*, 571.5*, 571.6x* 
Diabetes (mild to moderate) 250.0x-250.3x*, 250.7x* 
Hemiplegia or paraplegia 342.x*, 344.1* 
Moderate or severe renal disease 582.x*, 583.0-583.7*, 585*, 586*, 588.x* 
Diabetes with end organ damage 250.4x-250.6x* 
Any malignancy (except colon or rectal) including 
lymphoma or leukaemia 
140.x-152.x*, 155.x-172.0*, 174.x-195.8*, 200.x-208.x* 
Moderate or severe liver disease 572.2-572.8*, 456.0-456.21* 
Metastatic solid tumour 196.x-199.1 
AIDS 042.x-044.x 
Angina‡ 411.1*, 413.0*, 413.1*, 413.9* 
Essential hypertension‡ 401.x 
Cardiac arrhythmias‡ 426.x-427.x 
Previous pulmonary embolism‡ 415.1 
Cardiac valve disease‡ 394.x-397.0*, 424.0-424.3* 
Inflammatory bowel disease‡ 555.x*, 556.x* 
Other neurological condition‡ a 332.x-336.x*, 340.x*, 341.x*, 343.x*, 345.x*, 358.x*, 359.x* 
Major psychiatric conditions‡ b 295.x*, 296.x*, 298.0* 
* included in definition of a comorbidity if they are listed either in the index or prior hospital discharge; other 
codes only included if they are recorded prior to index admission 
‡ not included as part of Charlson Comorbidity Index 
a includes multiple sclerosis, Parkinson’s disease, other abnormal movement disorders, epilepsy, spinocerebellar 
disease, anterior horn disease, other diseases of spinal cord, other demyelinating diseases of CNS, cerebral palsy, 
myoneural disorders, muscular dystrophies. 
b includes schizophrenia, bipolar disease and depressive psychosis  
 
Extent of disease for each individual was categorised into local, regional, distant and unknown based 
on data from the Cancer Registry.14 We also collected demographic details of patients; age (in five 
categories), sex, ethnicity (Māori, Pacific, Asian and NZ European/Other) and small area deprivation 
using the NZ Deprivation Index (NZDep) aggregated into quintiles.15  
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Mortality data were obtained by linking study patients to the New Zealand national mortality database, 
with follow-up to the end of 2005. Patients whose deaths were not recorded in the mortality database 
were assumed to be still alive at the end of follow-up.  
Analysis—First, we assessed the prevalence of comorbidity in this cohort, and identified factors 
associated with its occurrence. We calculated counts and age/sex standardised proportions of Charlson 
comorbidity scores, and individual comorbid conditions. We examined multivariate (including age, 
sex, ethnicity, NZ Deprivation quintiles and extent of disease) predictors of higher Charlson 
comorbidity index scores using linear regression with a log transformation for the uncategorised 
Charlson scores. 
Second, we investigated the impact of comorbidity on risk of in-hospital death, length of stay and 5-
year all-cause survival. We first assessed the effects of comorbidity on these outcomes in age and sex 
adjusted models, and then adjusted additionally for ethnicity, NZ deprivation quintiles and extent of 
disease. We developed separate models for comorbidity measured using the Charlson co-morbidity 
score (categorised as 1, 2 and 3+) and the individual conditions listed in Table 1. 
In-hospital death 
Multivariable logistic regression was used to investigate in-hospital death, using either the 
index admission if it was the surgical resection of colorectal cancer or admission for primary 
resection occurring within 3 months of the index admission. All other admissions were 
excluded from analyses (N= 1311).  
Length of stay  
The effect of comorbidity on length of hospital stay was examined using linear regression, 
with log transformation of length of stay data. The same subset of data used in the analysis of 
in-hospital death was used for this analysis. The estimated parameters provide a (logged) 
measure of unit change in the outcome variable for every unit increase in the independent 
variable, e.g. if β = 0.14 in a regression of length of stay against Charlson score, then every 
standardised unit increase in Charlson score (e.g. increase of 1) is predicted to result in 
exp(0.14)=1.15—i.e. a 15% increase in days of length of stay.  
5-year all-cause survival 
Cox proportional hazards models were used to investigate 5-year all-cause survival. Hazard 
ratios (HR) are interpreted in the same way as relative risks with a HR>1 meaning that those 
with a given comorbidity score or condition have higher mortality and therefore poorer 5-year 
survival than those without the specified comorbidity. 
Ethics—Approval for this study was granted by the New Zealand Multi-Region Ethics Committee. 
Results 
A total of 11,524 patients met the eligibility criteria for the study. Table 2 shows the 
characteristics of the cohort. The cohort comprised approximately equal numbers of 
males and females, was predominantly non-Maori non-Pacific non-Asian, and more 
than 80% were aged 60 years or older.  
Prevalence and predictors of comorbidity—Table 3 shows the counts and age-sex 
standardised proportions for Charlson scores. As expected there was a highly skewed 
distribution of comorbidity scores with the majority of individuals having a Charlson 
score of 0. Males were somewhat more likely to have a Charlson score of 3 or more 
compared with females (10.3% compared with 7.5%).  
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Table 2. Characteristics of cohort 
 
Patient factors N % 
Total  11524 100.0 
Sex Male 
Female 
5477 
6047 
47.5 
52.5 
Prioritised ethnicity Maori 
Pacific 
Asian 
Euro/other 
324 
80 
119 
11001 
2.8 
0.7 
1.0 
95.5 
Age group 25–50yrs 
51–60yrs 
61–70yrs 
71–80yrs 
>80yrs 
643 
1392 
3209 
4028 
2252 
5.6 
12.1 
27.9 
35.0 
19.5 
NZDeprivation quintile missing 
1 
2 
3 
4 
5 
607 
1405 
1980 
2486 
2945 
2101 
5.3 
12.2 
17.2 
21.6 
25.6 
18.2 
Extent of disease Local 
Regional 
Distant 
Unknown 
2847 
5828 
2271 
578 
24.7 
50.6 
19.7 
5.0 
 
Charlson scores increased with age, and Māori and Pacific people had higher scores 
than Asian or NZ European/Other (e.g. the proportions with Charlson scores of 3 or 
more were 17.7%, 17.1%, 10.3 and 10.1% respectively). Increasing extent of disease 
was related to an increasing proportion of individuals with a Charlson score of 3+, 
although the group with unknown extent of disease had considerably higher Charlson 
scores than any other group (proportions with Charlson scores of 3+ were 8.8%, 9.5% 
and 12.0% for those with localised, regional and distant disease respectively. 18.8% 
of those with unknown extent of disease had Charlson scores of 3+).  
 
Table 3. Charlson scores by sex, age, ethnicity NZDeprivation quintile and extent 
of disease; numbers age and sex-standardised * proportions 
 
Charlson Scores** 
0 1 2 3+ 
Variable 
 
N % N % N % N % 
Sex Female 
Male 
4200 
3532 
69.5 
64.5 
1033 
980 
17.1 
17.9 
344 
374 
5.7 
6.8 
456 
566 
7.5 
10.3 
Age 25-50yrs 
51-60yrs 
61-70yrs 
71-80yrs 
>80 yrs 
587 
1147 
2331 
2473 
1194 
91.3 
82.4 
72.6 
61.4 
53.0 
37 
155 
493 
826 
502 
5.8 
11.1 
15.4 
20.5 
22.3 
5 
34 
157 
293 
229 
0.8 
2.4 
4.9 
7.3 
10.2 
13 
55 
215 
416 
323 
2.0 
4.0 
6.7 
10.3 
14.3 
Extent of disease Local 
Regional 
Distant 
Unknown 
1901 
3900 
1620 
311 
62.0 
61.5 
61.8 
52.6 
530 
1050 
335 
98 
20.1 
19.5 
15.8 
16.3 
179 
348 
139 
52 
9.2 
9.5 
10.4 
12.3 
226 
518 
171 
107 
8.8 
9.5 
12.0 
18.8 
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Charlson Scores** 
0 1 2 3+ 
Variable 
 
N % N % N % N % 
Ethnicity Māori 
Pacific 
Asian 
Euro/Other 
187 
51 
84 
7410 
49.5 
40.0 
60.0 
61.5 
62 
13 
22 
1916 
21.0 
29.0 
24.0 
18.6 
20 
6 
4 
688 
11.9 
13.9 
4.7 
9.8 
49 
8 
9 
956 
17.7 
17.1 
11.3 
10.1 
NZDeprivation 1 
2 
3 
4 
5 
Missing 
963 
1334 
1672 
1959 
1365 
439 
61.4 
61.1 
61.1 
60.9 
60.2 
63.6 
231 
337 
458 
521 
374 
92 
18.4 
18.1 
19.4 
18.8 
19.3 
18.3 
93 
118 
160 
180 
132 
35 
11.0 
9.7 
10.5 
9.3 
8.9 
9.8 
110 
187 
192 
275 
218 
40 
9.2 
11.1 
9.0 
11.0 
11.6 
8.3 
* age and sex standardised to the age and sex structure of the cohort population 
** higher scores indicate higher levels of comorbidity 
 
Table 4 shows the comorbidity counts and age-sex standardised prevalence for 
conditions with a prevalence greater than 5%. Prevalence was greater for males than 
females for all conditions, with the exception of essential hypertension. For all 
conditions, prevalence tended to increase with age, although fewer individuals had 
diabetes in the >80 yrs age group than in the 71–80 yrs age group. Those with 
unknown extent of disease had notably higher prevalence of all conditions. Prevalence 
of essential hypertension and diabetes was greater among Maori and Pacific patients 
than Asian and NZ European/Other.  
Maori also had a greater proportion with chronic respiratory disease, and Pacific had 
greater proportions with cerebrovascular disease and congestive heart failure. NZ 
European/Other had the greatest prevalence of cardiac arrhythmia and angina. The 
prevalence of recorded essential hypertension and chronic respiratory disease 
increased with increasing deprivation, while for other conditions no clear patterns 
were evident by deprivation group. 
When we investigated the relationship between covariates and Charlson scores using 
multiple regression analysis, we found that increasing age, ethnicity (Māori and 
Pacific), sex (male), extent of disease and NZ deprivation (quintile 5) were all 
significantly associated with higher Charlson scores even after adjustment for other 
variables in the models (results available from authors). 
Impact of comorbidity on outcomes—Tables 5a and 5b shows the odds ratios, 
parameter estimates and hazard ratios with 95% confidence intervals for regression 
models examining in-hospital death, length of stay and 5-year survival respectively. 
The Charlson scores were significantly associated with increased risks of in-hospital 
death with odds ratios monotonically increasing with increasing Charlson scores 
(Table 5a).  
For individual conditions, there were significantly increased odds of in-hospital death 
for those with chronic respiratory disease, cardiac arrhythmia, previous myocardial 
infarction and cerebrovascular accidents, while those with recorded essential 
hypertension and angina had significantly decreased odds of in-hospital death (Table 
5b). 
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Table 4. Prevalence of selected conditions* by sex, age, ethnicity NZ Deprivation quintile and extent of disease; numbers, age and sex-
standardised * proportions 
Variable Essential 
Hypertension 
Chronic Respiratory 
Disease 
Diabetes Cardiac 
Arrhythmia 
Myocardial 
Infarction 
Angina Congestive Heart 
Failure 
Cerebrovascular 
Accident 
 N % N % N % N % N % N % N % N % 
Sex Female 959 15.9 569 9.4 538 8.9 457 7.6 369 6.1 388 6.4 362 6.0 314 5.2 
 
Male 841 15.4 585 10.7 569 10.4 580 10.6 549 10.0 504 9.2 349 6.4 348 6.4 
Prioritised Ethnicity Maori 59 18.2 54 16.7 62 19.1 24 7.4 25 7.7 19 5.9 26 8.0 14 4.3 
 
Pacific 14 17.5 6 7.5 16 20.0 3 3.8 5 6.3 5 6.3 8 10.0 6 7.5 
 
Asian 13 10.9 5 4.2 15 12.6 4 3.4 9 7.6 4 3.4 6 5.0 4 3.4 
 
Euro/Other 
European/Other 
1714 15.6 1089 9.9 1014 9.2 1006 9.1 879 8.0 864 7.9 671 6.1 638 5.8 
Age group 25-50yrs 14 2.2 17 2.6 20 3.1 2 0.3 5 0.8 5 0.8 2 0.3 2 0.3 
 
51-60yrs 113 8.1 80 5.7 93 6.7 30 2.2 39 2.8 36 2.6 14 1.0 28 2.0 
 
61-70yrs 419 13.1 276 8.6 314 9.8 174 5.4 188 5.9 211 6.6 108 3.4 126 3.9 
 
71-80yrs 770 19.1 480 11.9 466 11.6 454 11.3 394 9.8 392 9.7 288 7.1 275 6.8 
 
81+yrs 484 21.5 301 13.4 214 9.5 377 16.7 292 13.0 248 11.0 299 13.3 231 10.3 
NZ Deprivation Quintile 1 185 13.2 119 8.5 121 8.6 144 10.2 115 8.2 91 6.5 75 5.3 88 6.3 
 
2 279 14.1 186 9.4 183 9.2 169 8.5 150 7.6 142 7.2 138 7.0 105 5.3 
 
3 385 15.5 237 9.5 228 9.2 216 8.7 194 7.8 191 7.7 137 5.5 142 5.7 
 
4 511 17.4 327 11.1 289 9.8 268 9.1 255 8.7 257 8.7 186 6.3 180 6.1 
 
5 360 17.1 234 11.1 243 11.6 200 9.5 165 7.9 166 7.9 144 6.9 115 5.5 
 
Missing 80 13.2 51 8.4 43 7.1 40 6.6 39 6.4 45 7.4 31 5.1 32 5.3 
Extent of Disease Distant 323 14.2 203 8.9 203 8.9 168 7.4 155 6.8 144 6.3 127 5.6 94 4.1 
 Local 467 16.4 282 9.9 273 9.6 283 9.9 229 8.0 255 9.0 171 6.0 146 5.1 
 Regional 878 15.1 563 9.7 563 9.7 494 8.5 457 7.8 429 7.4 316 5.4 363 6.2 
 Unknown 132 22.8 106 18.3 68 11.8 92 15.9 77 13.3 64 11.1 97 16.8 59 10.2 
* conditions with a prevalence of 5% or greater in the cohort ** age and sex standardised to the age and sex structure of the cohort population 
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Table 5a. Odds ratios, parameter estimates and hazard ratios (95% CI) for regression models with Charlson scores and covariates 
predicting in-hospital death, length of stay or 5-year survival respectively 
In Hospital Death Length of Stay Survival over 5 years 
Odds Ratios Parameter Estimates (β) Mortality hazard Ratios 
Charlson Score* 
Model 1a Model 1 b Model 2a Model 2 b Model 3a Model 3b 
1 2.41 (1.79, 3.24) 2.51 (1.87, 3.39) 0.03 (-0.02, 0.08) 0.03 (-0.02, 0.08) 1.21 (1.12, 1.30) 1.26 (1.17, 1.37) 
2 3.43 (2.36, 4.98) 3.52 (2.41, 5.13) 0.02 (-0.05, 0.09) 0.02 (-0.05, 0.09) 1.73 (1.54, 1.94) 1.75 (1.55, 1.97) 
3+ 4.52 (3.32, 6.14) 4.81 (3.52, 6.58) 0.14 (0.08, 0.20) 0.14 (0.08, 0.20) 1.95 (1.75, 2.17) 2.02 (1.81, 2.25) 
* Charlson score = 0 is reference group; a adjusted for age (6 categories) and sex only b adjusted for age (6 categories) , sex, ethnicity, NZ deprivation quintiles and extent of disease.  
 
Table 5b. Odds ratios, parameter estimates and hazard ratios (95% CI) for regression models with comorbidity conditions and 
covariates predicting in-hospital death, length of stay or 5-year survival respectively 
In Hospital Death Length of Stay Survival over 5 years 
Odds Ratios Parameter Estimates (β) Hazard Ratios 
Comorbid Conditionsc 
Model 1a Model 1 b Model 2a Model 2 b Model 3a Model 3b 
Essential Hypertension 0.73 (0.53, 1.00) 0.72 (0.52, 0.99) -0.11 (-0.17, -0.04) -0.10 (-0.17, -0.04) 0.98 (0.90, 1.06) 0.98 (0.90, 1.07) 
Chronic Respiratory Disease 2.32 (1.74, 3.09) 2.40 (1.79, 3.22) 0.21 (0.13, 0.28) 0.21 (0.14, 0.29) 1.22 (1.11, 1.34) 1.20(1.17, 1.41) 
Diabetes 1.00 (0.69, 1.45) 1.01 (0.69, 1.46) 0.17 (0.10, 0.25) 0.17 (0.09, 0.24) 1.00 (0.98, 1.03) 1.00 (0.98, 1.03) 
Cardiac Arrhythmia 1.30 (0.92, 1.84) 1.42 (1.00, 2.02) -0.05 (-0.14, 0.04) -0.04 (-0.12, 0.05) 1.08 (0.97, 1.20) 1.15 (1.03, 1.29) 
Myocardial Infarction 2.19 (1.59, 3.03) 2.20 (1.59, 3.06) 0.13 (0.05, 0.22) 0.13 (0.04, 0.21) 1.26 (1.13, 1.40) 1.22 (1.10, 1.37) 
Angina 0.62 (0.41, 0.95) 0.59 (0.38, 0.90) -0.01 (-0.10, 0.07) 0.00 (-0.09, 0.08) 0.86 (0.77, 0.97) 0.88 (0.78, 0.99) 
Congestive Heart Failure 1.20 (0.81, 1.78) 1.19 (0.80, 1.78) -0.04 (-0.15, 0.07) -0.04 (-0.15, 0.06) 1.31 (1.16, 1.49) 1.25 (1.11, 1.42) 
Cerebrovascular Accident 2.10 (1.37, 3.20) 2.12 (1.38, 3.25) 0.00 (-0.12, 0.12) 0.05 (-0.07, 0.17) 1.15 (0.99, 1.33) 1.15 (0.99, 1.34) 
a adjusted for age (6 categories) and sex only; b adjusted for age (6 categories), sex, ethnicity, NZ deprivation quintiles and extent of disease; c only comorbidities with prevalence>5% reported. 
Other conditions included in model include peripheral vascular disease, dementia, connective tissue disease, GI ulcer disease, mild liver disease, hemiplegia/paraplegia, renal disease, any 
malignancy, moderate to severe liver disease, metastatic solid tumour, previous pulmonary embolism, cardiac valve disease, IBD, other neurological conditions, major psychiatric conditions; 
Bolded estimates are statistically significant 
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The associations with length of hospital stay were less clear, with a significant 
association only seen among those with Charlson scores of 3+, compared with 0. That 
is, people with a Charlson score of 3 or more had a 15% (95% CI 8%-22%) increase 
in length of stay (exp(0.14)=1.15). Those with chronic respiratory disease, diabetes 
and previous myocardial infarction had significantly longer length of stays compared 
to those without the specified condition, while those with recorded essential 
hypertension had significantly shorter stays.  
There was a monotonic increase in mortality rate (hazard) reflecting poorer all-cause 
5-year survival with increasing Charlson scores. Some individual conditions were 
associated with higher 5-year mortality, particularly congestive heart failure (HR 
=1.25 95% CI 1.11-1.42), previous myocardial infarction (HR =1.22 95% CI 1.10-
1.37) chronic pulmonary disease (HR =1.20 95% CI 1.17-1.41) and cardiac 
arrhythmia (HR =1.15 95% CI 1.03-1.29). However, a diagnosis of angina was 
associated with a significantly lower 5-year mortality rate (HR=0.88 95% CI= 0.78-
0.99).  
Discussion 
In a large cohort of patients with colon cancer, we found that comorbidity was 
common, associated with increasing age, and among males, Māori and Pacific people, 
those with unknown extent of disease at diagnosis and those living in the most 
deprived quintile of New Zealand. Comorbidity was associated with a higher risk of 
in-hospital death, longer lengths of hospital stay and lower 5-year survival.  
In some respects these results are self-evident; those who are sicker have poorer 
outcomes. However there has been very little work specifically investigating the 
impact of comorbidity among patients in the New Zealand context.6-8  
Comorbidity affects nearly every aspect of health care both for the individual patient 
with comorbidity, and for health care providers managing such patients. Comorbidity 
has been shown to affect treatment choice, risk of complications, quality of life, 
mortality, and health care resource use.2-6 It is therefore important to understand the 
patterns and impact of comorbidity in New Zealand. 
Our results are largely consistent with other research. For example, many studies have 
found that comorbidity is common among patients with cancer generally, and 
colorectal cancer specifically.6,16–28 The highly skewed distribution of comorbidity 
scores with only a small minority of patients scoring 3 or more is consistently seen.17 
Not surprisingly, Charlson scores were higher and all individual conditions were more 
common among older people; as has been reported previously, comorbidity was 
higher among males, Māori and those living in more deprived areas.5  
Many studies have found that mortality risk increases, and survival decreases, with 
increasing global comorbidity score.4,6,11,16,18,28–37 The magnitude of this association 
varies depending on the setting of the study, the methods used to measure 
comorbidity, and the timing of mortality or survival (e.g. in-hospital death, 1-year or 
5-year mortality/survival).  
Fewer studies have investigated the role of comorbidity with length of hospital stay, 
and the results are somewhat less consistent. Generally however, those with higher 
comorbidity have longer stays in hospital.30 37 38 Of note is that the rules relating to the 
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coding of comorbid conditions in New Zealand state that comorbid conditions should 
be coded if they co-exist or arise during a given episode of care and if they affect 
patient management in a way that might extend length of hospital stay. This approach 
is likely to result in an emphasis on the most active and clinically important 
conditions, and of course introduces some circularity to the argument that routinely 
recorded comorbidity affects length of stay. 
The patterns for individual conditions were somewhat variable, although most 
individual conditions adversely affected one or more of the outcomes we investigated. 
Recorded essential hypertension and angina were notable exceptions to this rule, in 
that patients with these conditions had significantly better outcomes than others. This 
finding is consistent with other studies21 29 30 and is likely to be due to a type of 
information bias where those who have major, potentially life-threatening conditions 
are less likely to have conditions that are common and less serious recorded. As a 
result, those that do have these latter conditions, paradoxically, tend to be healthier 
than those with other comorbidities, and as a result have better outcomes. 
Another interesting finding is that those with unknown extent of disease are 
considerably more likely to have a Charlson score of 3+, and more likely to have most 
of the individual conditions than those with recorded extent of disease. It seems likely 
that one of the reasons that these patients have not been staged is that they may be too 
unwell to be treated for their cancer, which is consistent with what is often 
anecdotally assumed. 
Strengths and weaknesses of this study—The main strengths of this study are that it 
is based on a large cohort of patients, we restricted the study to those with a specific 
diagnosis to minimise confounding due to primary condition, and we used both 
individual conditions and a global measure of comorbidity (Charlson comorbidity 
index) to measure comorbidity. 
The key weakness of the study was that we used routinely collected administrative 
data to identify comorbidity in the patients. Generally data obtained directly from 
medical notes is considered superior, however collecting such data is time-consuming 
and difficult. Also, while comorbidities tend to be more common if data are collected 
from medical notes, these data are not complete or error-free, nor are administrative 
data a subset of these data.9 33 39 40  
In a previous publication we compared data collected from medical notes to those 
obtained from routine data sources and found that while there were differences 
between these data sources, both provided reasonable risk adjustment within 
multivariable models.9  
We used the Charlson comorbidity index which is a well-established method of 
measuring comorbidity. However, there are issues with using this index. It was 
developed over 20 years ago on a relatively small group of patients in the US.11 It 
includes some conditions which are unlikely to have a major impact on outcomes 
currently (e.g. peptic ulcer disease), it excludes some that are likely to have an impact 
(e.g. non-cerebrovascular neurological conditions), and it assumes that the impact of 
multiple conditions is additive on a relative scale.6 However, to date no gold standard 
measure of comorbidity has been developed. 
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We have also only included patients with colon cancer for the reasons outlined in the 
introduction. These findings are probably generalisable to other patient groups, but it 
is not assured. 
The findings of this study support the importance of comorbidity in terms of health 
service and patient impact. It is the first study in New Zealand to have used routinely 
collected comorbidity data for this purpose. These initial analyses suggest that general 
comorbidity, measured by Charlson scores, is strongly associated with in-hospital 
death, length of stay and 5-year survival. The relationships among individual 
comorbid conditions and these outcome variables are less consistent, although most 
major comorbid conditions were associated with a negative effect on one or more of 
the adverse outcomes we measured.  
Further research is needed to confirm the impact of comorbidity on other groups, and 
to investigate whether the measurement of comorbidity can be improved in New 
Zealand.  
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